A New Switch Hitter for Type 1 Diabetes Discovered

Pancreatic cells are more adaptable and possess a greater potential for self-healing than previously assumed For decades, the prevailing wisdom was that beta cells could not regenerate and that their loss in type 1 diabetes (T1D) was irreversible—the reason why people with T1D require insulin injections for life. JDRF-funded research is helping rewrite the textbook […]

Research Teamwork is Key to Curing Type 1 Diabetes

JDRF takes center stage at Capitol Hill briefing on accelerating biomedical research progress Richard A. Insel, M.D., JDRF’s Chief Scientific Officer, joined other research leaders at a Congressional briefing on, “How the Research-by-Consortia Model Will Lead to Faster Cures” held recently in Washington D.C. The briefing brought together biomedical leaders from foundations, industry, government, and […]

JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

Updated Sept. 18, 2014 JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem […]

Oxygen – A Key Ingredient of Life

JDRF partners with Beta-O2 Technologies to develop a novel implantable encapsulation device for type 1 diabetes The dream for everyone with type 1 diabetes (T1D) is to permanently restore their body’s lost ability to produce insulin. This defines a cure for T1D and remains a top priority for JDRF. As we work towards this longer-term […]

Rebalancing the Immune System

Novel therapy to increase beneficial immune cells shows promise in pilot type 1 diabetes clinical study Type 1 diabetes (T1D) is caused when a person’s immune system mistakenly destroys their insulin-producing beta cells. How and why this misguided attack begins remains a mystery, but JDRF research has helped shed light on the disease process, opening […]

Potential Breakthrough in Encapsulation Technology

JDRF-funded researchers develop novel method of protecting islets for implantation into people with type 1 diabetes Pancreatic islet transplantation has restored insulin independence in some individuals with type 1 diabetes (T1D), but the procedure is not widely available due to the limited supply of donated islets and the need for strong immunosuppressive drugs to prevent […]

Top 10 Advances in T1D Research

JDRF-supported progress in fiscal year 2014 JDRF sets ambitious goals for progress in type 1 diabetes (T1D) research each year because our supporters inspire us to aim higher. We invite you to read about the real impact our strategic plan is making and hope you are as inspired as we are as each of these […]

15th Annual Spring Research Briefing

Thomas P. Brobson, National Director, Research Investment Opportunities speaks about the latest advances in type 1 diabetes research at the Annual Spring Research Briefing held at the Sheraton Needham Hotel. Mr. Brobson’s Presentation is split into four parts, see below.                                 […]

Redefining the Diagnosis of Type 1 Diabetes

Updated criteria could open new possibilities for intervention before symptoms appear JDRF is leading a pertinent discussion in the diabetes field about what defines a diagnosis of type 1 diabetes (T1D). At the 14th Annual Rachmiel Levine Diabetes and Obesity Symposium today, Richard Insel, M.D., JDRF’s chief scientific officer, reviewed evidence supporting the need to […]

14th Annual Spring Research Briefing

The 14th Annual Spring Research Briefing was held on April 9, 2013 at the Sheraton Needham Hotel. Dr. Julia Greenstein, JDRF’s Vice President of Cure Therapies, started the evening by providing an overview of JDRF’s research portfolio.  JDRF is driving research across the entire scientific spectrum, from discovery in the laboratory to delivery of new […]